对于许多记忆障碍的研究日见增多，包括那些由神经变性疾病，外伤性脑损伤(TBI)，血管疾病，或脑发育异常诱发的记忆障碍，这些疾病都存在记忆相关通路中共同的病理特征。

2015年5月发表于《药理学趋势》(Trends in pharmacological sciences)杂志的一篇文章，对记忆障碍的常规治疗进行了综述。(Trends Pharmacol Sci.2015 May 7. pii: S0165-6147(15)00076-0. doi: 10.1016/j.tips.2015.04.004. [Epub ahead of print])

研究者认为突触的结构和功能障碍是基础病理生理学的核心，是记忆障碍的关键点。通过靶向突触损失和功能障碍进行记忆障碍的治疗，一般是通过减缓、停止或逆转该病症在突触水平的发展，可以突触分子中相关蛋白如蛋白激酶C(PKC)和脑源性神经营养因子的( BDNF)为治疗靶点，这些蛋白有在治疗多种形式的记忆障碍方面，有一定普遍治疗价值。可以单独干扰记忆障碍患者的其中一种蛋白，也可以将这些蛋白的通路作为辅助治疗的药物靶标。

Towards universal therapeutics for memory disorders.

Sun MK1,Nelson TJ2,Alkon DL2.

Author information

Abstract

Evidence is accumulating that many memory disorders, including those due to neurodegenerative diseases, traumatic brain injury (TBI), vascular disease, or abnormal brain development, share common features of memory-related pathology. Structural and functional deficits of synapses are at the core of the underlying pathophysiology, constituting a critical point of convergence in memory disorders. Memory therapeutics that target synaptic loss and dysfunction - that is, to slow, halt, or reverse progression of the disorders at the level of synapses, via synaptogenic molecular cascades such as those of protein kinase C (PKC) and brain-derived neurotrophic factor (BDNF) - possess universal therapeutic value for many forms of memory disorder. They may be useful either as standalone interventions for patients with memory disorders or as adjuncts to drugs that target the underlying pathology.